Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Randomized, Double-Masked, Vehicle-Controlled Evaluation of the Efficacy, Safety, and Tolerability of EBI-005 in Subjects With Moderate to Severe Ocular Allergic Conjunctivitis

NCT02492321 is registered in ClinicalTrials.gov with Eleven Biotherapeutics as lead sponsor.

NCT NCT02492321
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02492321 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Randomized, Double-Masked, Vehicle-Controlled Evaluation of the Efficacy, Safety, and Tolerability of EBI-005 in Subjects With Moderate to Severe Ocular Allergic Conjunctivitis
Lead sponsor
Eleven Biotherapeutics
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2015
Completion date
December 31, 2015
Enrollment
250 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

allergic conjunctivitis (ac)